CytoSorbents to Report Q1 2014 Operating and Financial Results

        CytoSorbents to Report Q1 2014 Operating and Financial Results  PR Newswire  MONMOUTH JUNCTION, N.J., May 8, 2014  MONMOUTH JUNCTION, N.J., May 8, 2014 /PRNewswire/ --CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report Q1 2014 financial results after the market close on Wednesday, May 14, 2014.  CytoSorbents Logo  CytoSorbents' management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q1 2014 and answer pre-submitted questions as time permits.  Conference Call Details: Date: Wednesday, May 14, 2014 Time: 4:15 PM Eastern Participant Dial-In: 480-629-9809 Live Presentation Webcast:  It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link:  An archived recording of the conference call will be available under the Investor Relations section of the Company's website at  Investors are encouraged to submit their questions in advance as soon as possible to Ms. Amy Vogel at  About CytoSorbents Corporation  CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website:  Forward-Looking Statements This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on March 31, 2014, which is available at  Please Click to Follow us on Facebook and Twitter  Logo -  SOURCE CytoSorbents Corporation  Website: Contact: Company Contact: CytoSorbents Corporation, Dr. Phillip Chan, MD, PhD, Chief Executive Officer, (732) 329-8885 ext. *823,, Investor Contact: CytoSorbents Corporation, Amy Vogel, (732) 329-8885 ext. *825,  
Press spacebar to pause and continue. Press esc to stop.